Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Genentech, Inc. - Product Pipeline Review - 2016 Summary
Global Markets Direct's, 'Genentech, Inc. - Product Pipeline Review - 2016', provides an overview of the Genentech, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Genentech, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Genentech, Inc. - The report provides overview of Genentech, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Genentech, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Genentech, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy
- Evaluate Genentech, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Genentech, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Genentech, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Genentech, Inc. Snapshot 6 Genentech, Inc. Overview 6 Key Information 6 Key Facts 6 Genentech, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Genentech, Inc. - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Partnered Products 14 Pipeline Products - Out-Licensed Products 16 Genentech, Inc. - Pipeline Products Glance 18 Genentech, Inc. - Late Stage Pipeline Products 18 Genentech, Inc. - Clinical Stage Pipeline Products 19 Genentech, Inc. - Early Stage Pipeline Products 22 Genentech, Inc. - Drug Profiles 25 crenezumab 25 etrolizumab 27 lampalizumab 29 taselisib 31 duligotuzumab 33 ipatasertib 35 polatuzumab vedotin 37 quilizumab 39 RG-6046 40 RG-7745 41 BFKB-8488A 42 BTCT-4465A 43 DMUC-4064A 44 Drug for Inflammatory Diseases 45 DSTA-4637S 46 GDC-0134 47 GDC-0927 48 lifastuzumab vedotin 49 RG-6024 51 RG-6029 52 RG-7741 53 RG-7828 54 RG-7842 55 RG-7845 56 RG-7882 57 RG-7888 58 RG-7893 59 CS-3 60 G-007LK 61 G-244LM 62 GNE-293 63 GNE-317 64 GNE-3511 65 GNE-555 66 GNE-7915 67 GNE-892 68 MAb-30D8 69 Monoclonal Antibodies to Target CD98hc and BACE for Alzheimer's Disease 70 Monoclonal Antibody Conjugate for B-Cell Non Hodgkin's Lymphoma 71 Monoclonal Antibody Conjugates for Oncology 72 Monoclonal Antibody to Inhibit HtrA1 for Age Related Macular Degeneration 73 Monoclonal Antibody to Inhibit Tau for Alzheimer's Disease and Neurodegenerative Disorders 74 MV-1 75 pictilisib 76 Small Molecule to Inhibit BACE1 for Alzheimer's Disease 78 Small Molecule to Inhibit MAP4K4 for Cancer 79 Small Molecule to Inhibit TYK2 for Psoriasis and IBD 80 Small Molecules to Inhibit IRAK4 for Immunology and Oncology 81 Small Molecules to Inhibit JAK2 for Cancer 82 Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms 83 Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma 84 Small Molecules to Inhibit NAMPT for Cancer 85 Small Molecules to Inhibit PI3-Kinase Delta for Inflammatory and Leukocyte Disorders 86 Monoclonal Antibody Conjugated for Cancer 87 Small Molecule 2 for Undisclosed Indication 88 Small Molecule to Inhibit ITK for Asthma 89 Small Molecules 1 for Undisclosed Indication 90 Small Molecules for Central Nervous System Disorders 91 Small Molecules for Undisclosed Indication 92 Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation 93 Small Molecules to Inhibit EGFR for Non-Small Cell Lung Cancer 94 Small Molecules to Inhibit Jak1/2 for Hematopoietic and Immunologic diseases 95 Small Molecules to Inhibit Ubiquitin Specific Protease for Oncology 96 Genentech, Inc. - Pipeline Analysis 97 Genentech, Inc. - Pipeline Products by Target 97 Genentech, Inc. - Pipeline Products by Route of Administration 100 Genentech, Inc. - Pipeline Products by Molecule Type 101 Genentech, Inc. - Pipeline Products by Mechanism of Action 102 Genentech, Inc. - Recent Pipeline Updates 105 Genentech, Inc. - Dormant Projects 112 Genentech, Inc. - Discontinued Pipeline Products 113 Discontinued Pipeline Product Profiles 114 Genentech, Inc. - Company Statement 119 Genentech, Inc. - Locations and Subsidiaries 120 Head Office 120 Other Locations & Subsidiaries 120 Genentech, Inc. - Key Manufacturing Facilities 121 Appendix 122 Methodology 122 Coverage 122 Secondary Research 122 Primary Research 122 Expert Panel Validation 122 Contact Us 122 Disclaimer 123
List of Tables
Genentech, Inc., Key Information 11 Genentech, Inc., Key Facts 11 Genentech, Inc. - Pipeline by Indication, 2016 13 Genentech, Inc. - Pipeline by Stage of Development, 2016 17 Genentech, Inc. - Monotherapy Products in Pipeline, 2016 18 Genentech, Inc. - Partnered Products in Pipeline, 2016 19 Genentech, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 20 Genentech, Inc. - Out-Licensed Products in Pipeline, 2016 21 Genentech, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 22 Genentech, Inc. - Phase III, 2016 23 Genentech, Inc. - Phase II, 2016 24 Genentech, Inc. - Phase I, 2016 25 Genentech, Inc. - Preclinical, 2016 27 Genentech, Inc. - Discovery, 2016 29 Genentech, Inc. - Pipeline by Target, 2016 102 Genentech, Inc. - Pipeline by Route of Administration, 2016 105 Genentech, Inc. - Pipeline by Molecule Type, 2016 106 Genentech, Inc. - Pipeline Products by Mechanism of Action, 2016 107 Genentech, Inc. - Recent Pipeline Updates, 2016 110 Genentech, Inc. - Dormant Developmental Projects,2016 117 Genentech, Inc. - Discontinued Pipeline Products, 2016 118 Genentech, Inc., Other Locations 125 Genentech, Inc., Key Manufacturing Facilities 126
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
